Related Experiment Videos
A lethal neurotoxic reaction after intraventricular methotrexate administration
1Department of Neurology, Academic Hospital Maastricht, University of Limburg, The Netherlands.
Abstract:
A case of a patient with leptomeningeal metastases from an adenocarcinoma of the lung is described. She developed a fatal neurologic reaction during intraventricular administration of methotrexate. No morphologic cause of death was found during autopsy. Similar cases of acute complications are discussed, and an outline of factors that might play a role in the pathophysiology of methotrexate neurotoxicity is given.
Insights
A patient experienced a fatal neurologic reaction after intraventricular methotrexate for lung adenocarcinoma leptomeningeal metastases. Autopsy revealed no cause, highlighting methotrexate neurotoxicity risks.
Area of Science:
- Neuroscience
- Oncology
- Pharmacology
Background:
- Leptomeningeal metastases from lung adenocarcinoma present significant treatment challenges.
- Intraventricular chemotherapy, including methotrexate, is a treatment option for leptomeningeal disease.
- Methotrexate neurotoxicity is a known but complex complication.
Observation:
- A case report details a patient with lung adenocarcinoma leptomeningeal metastases.
- The patient developed a fatal neurologic reaction during intraventricular methotrexate administration.
- Autopsy findings did not reveal a specific morphologic cause of death.
Findings:
- The described case suggests a potential for acute, fatal neurotoxicity from intraventricular methotrexate.
- The study discusses similar cases of severe adverse neurologic events.
- Factors contributing to methotrexate neurotoxicity pathophysiology are outlined.
Implications:
- This case underscores the critical need for careful patient monitoring during intraventricular methotrexate therapy.
- Understanding methotrexate neurotoxicity mechanisms is crucial for developing safer treatment protocols.
- Further research into predictive factors and management strategies for methotrexate-induced neurotoxicity is warranted.